S100A4 and breast carcinoma: ECM1 has previously been implicated in breast cancer metastasis and plays a critical role in its progression by activating cholesterol biosynthesis, inducing NOTCH-mediated endothelial feedback and regulating actin cytoskeletal architecture through alterations in S100A4 and Rho A, suggesting its utility as an adjuvant therapeutic agent (28–33).